ACTRN12614000330640已完成1 期
IPX234-B13-01: Evaluation of the Pharmacokinetics and Safety of Dihydroergotamine Administered Via Two Intranasal Delivery Devices in healthy volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- All
入选标准
- •Healthy male and female subjects between 18 years and 40 years of age inclusive at the time of Screening
排除标准
- •Presence of a clinically significant disorder including acute or chronic infections, or a malignant neoplasm, and/or involving disease in one or more of these organ systems: cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, dermatologic, hepatic, reproductive, endocrine, or neurologic/psychiatric, as determined by clinical investigators
- •An upper respiratory tract infection or any other acute illness, including active allergic rhinitis, at Screening or at Check-in for each treatment period that the investigator believes may interfere with the administration, nasal retention, or absorption of study drug; or any prior medical conditions that, in the opinion of the Investigator, would interfere or modify the nasal administration, retention, or absorption of study drug
研究者
相似试验
已完成
1 期
Evaluation of the Pharmacokinetics of Sublingual IPX237 in Healthy VolunteersDepressionACTRN12614000444684Impax Pharmaceuticals,A Division of Impax Laboratories, Inc.24
撤回
1 期
Evaluation of the pharmacokinetics and safety of multiple once-daily doses of IPX233 in healthy adult volunteersAttention Deficit Hyperactivity Disorder (ADHA)Neurological - Other neurological disordersMental Health - Other mental health disordersACTRN12614000518662Impax Laboratories, Inc20
已完成
1 期
Evaluation of the Pharmacokinetics of IPX233 Formulations in Healthy VolunteersAttention Deficit Hyperactivity Disorder (ADHD)Neurological - Other neurological disordersACTRN12613001073796Impax Pharmaceuticals,A Division of Impax Laboratories, Inc.20
进行中（未招募）
不适用
Evaluation of blood drug level profile, effect and safety after repeated administration of a slow release formulation of S-38844 in healthy male volunteersEUCTR2010-020197-42-DEInstitut de Recherches Internationales Servier27
已完成
不适用
Evaluation of the Pharmacokinetics of IPX231 (L0007, C0001) in Healthy SubjectsNeurological - Parkinson's diseaseParkinson's diseaseACTRN12613000973718Impax Laboratories, Inc.20